TRACON Pharmaceuticals Inc.

1.5100.00Vol 2.40K1Y Perf -46.26%
Nov 25th, 2022 00:56 DELAYED
BID1.49 ASK1.51
Open1.50 Previous Close1.51
Pre-Market- After-Market-
 - -  - -%
Target Price
10.00 
Analyst Rating
Strong Buy 1.00
Potential %
562.25 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
     31.34
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
10.47 
Earnings Rating
Strong Sell
Market Cap33.54M 
Earnings Date
14th Nov 2022
Alpha-0.01 Standard Deviation0.35
Beta1.60 

Today's Price Range

1.501.51

52W Range

1.243.79

5 Year PE Ratio Range

-1.10-1.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
7.60%
1 Month
-6.79%
3 Months
-24.88%
6 Months
-16.11%
1 Year
-46.26%
3 Years
-55.72%
5 Years
-94.51%
10 Years
-

TickerPriceChg.Chg.%
TCON1.510.00000.00
AAPL148.11-2.9600-1.96
GOOG97.60-1.2200-1.23
MSFT247.49-0.0900-0.04
XOM113.21-0.4000-0.35
WFC47.440.11000.23
JNJ177.240.23000.13
FB196.640.99000.51
GE88.140.27000.31
JPM136.740.26000.19
 
ProfitabilityValueIndustryS&P 500US Markets
-
-9 491.60
-9 491.60
-728.10
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.30-0.300.00
Q02 2022-0.29-0.31-6.90
Q01 2022-0.41-0.48-17.07
Q04 2021-0.40-0.400.00
Q03 2021-0.32-0.38-18.75
Q02 2021-0.34-0.58-70.59
Q01 2021-0.32-0.33-3.12
Q04 2020-0.34-0.318.82
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.11-237.50Negative
12/2022 QR0.080.00-
12/2022 FY-1.14-31.03Negative
12/2023 FY-1.0013.04Positive
Next Report Date-
Estimated EPS Next Report-0.30
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume2.40K
Shares Outstanding22.21K
Shares Float13.41M
Trades Count23
Dollar Volume3.61K
Avg. Volume70.94K
Avg. Weekly Volume59.57K
Avg. Monthly Volume81.00K
Avg. Quarterly Volume72.25K

TRACON Pharmaceuticals Inc. (NASDAQ: TCON) stock closed at 1.51 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 2.40K shares and market capitalization of 33.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. TRACON Pharmaceuticals Inc. CEO is Charles P. Theuer.

The one-year performance of TRACON Pharmaceuticals Inc. stock is -46.26%, while year-to-date (YTD) performance is -45.49%. TCON stock has a five-year performance of -94.51%. Its 52-week range is between 1.2434 and 3.79, which gives TCON stock a 52-week price range ratio of 10.47%

TRACON Pharmaceuticals Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 11.83, a price-to-sale (PS) ratio of 111.21, a price to cashflow ratio of 74.30, a PEG ratio of 2.32, a ROA of -154.29%, a ROC of -420.10% and a ROE of -464.65%. The company’s profit margin is -%, its EBITDA margin is -9 491.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from TRACON Pharmaceuticals Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.30 for the next earnings report. TRACON Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for TRACON Pharmaceuticals Inc. is Strong Buy (1), with a target price of $10, which is +562.25% compared to the current price. The earnings rating for TRACON Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

TRACON Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

TRACON Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.12, ATR14 : 0.09, CCI20 : -25.03, Chaikin Money Flow : -0.13, MACD : -0.05, Money Flow Index : 47.05, ROC : -0.66, RSI : 47.05, STOCH (14,3) : 42.86, STOCH RSI : 1.00, UO : 46.30, Williams %R : -57.14), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of TRACON Pharmaceuticals Inc. in the last 12-months were: Charles P. Theuer (Buy at a value of $131 553), Scott B Brown (Buy at a value of $7 858)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration (wet AMD). The company's pipeline consists of product candidates such as TRC105, TRC102, TRC253, TRC694, and TRC205. The lead product TRC105 is an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or programmed cell death protein 1 pathway.

CEO: Charles P. Theuer

Telephone: +1 858 550-0780

Address: 4350 La Jolla Village Drive, San Diego 92122, CA, US

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

60%40%

TipRanks News for TCON

Tue, 22 Nov 2022 14:35 GMT TRACON Pharmaceuticals (TCON) Receives a Buy from Maxim Group

- TipRanks. All rights reserved.

Thu, 11 Aug 2022 15:40 GMT Analysts Are Bullish on Top Healthcare Stocks: TRACON Pharmaceuticals (TCON), Outlook Therapeutics (OTLK)

- TipRanks. All rights reserved.

News

Stocktwits